Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Erlotinib Monotherapy in Patients with Advanced Non-small Cell Lung Cancer: An Effective Approach with Low Toxicity

ALEXANDROS ARDAVANIS, STELLA KOUMNA, IOANNIS FRAGOS, SAVVOULA MALLIOU, FLORA KYRIAKOU, IOANNIS MANTZARIS, ANDREAS SCORILAS and GERASSIMOS RIGATOS
Anticancer Research July 2008, 28 (4C) 2409-2415;
ALEXANDROS ARDAVANIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ardavanis@yahoo.com
STELLA KOUMNA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IOANNIS FRAGOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SAVVOULA MALLIOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FLORA KYRIAKOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IOANNIS MANTZARIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDREAS SCORILAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GERASSIMOS RIGATOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib (Tarceva) has been a field of intense research. This retrospective study was conducted to assess the efficacy of erlotinib and its impact on survival. Patients and Methods: Patients with stage IIIB or IV, advanced or recurrent metastatic NSCLC were included in the study and were administered erlotinib 150 mg daily, at different lines of treatment. Results: Thirty-six patients were included in the study: 29 (81%) male, 7 (19%) female. At the time of analysis, all patients had progressed and died. Median progression-free survival (PFS) was 4 months ± 2.43 months (range 0-8 months), whereas median overall survival (OS) was 7 months ± 2.65 months (range 3-15 months). Patients with ECOG performance status of 0 or 1 had better OS and significantly higher PFS rates. Overall response rate was 16.7%, while the disease control rate was 81% . Conclusion: Erlotinib is effective and well tolerated in pretreated patients with advanced NSCLC and a good performance status.

  • Advanced non-small cell lung cancer
  • erlotinib
  • monotherapy

Footnotes

  • Received January 23, 2008.
  • Revision received April 16, 2008.
  • Accepted April 22, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (4C)
Anticancer Research
Vol. 28, Issue 4C
July-August 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Erlotinib Monotherapy in Patients with Advanced Non-small Cell Lung Cancer: An Effective Approach with Low Toxicity
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Erlotinib Monotherapy in Patients with Advanced Non-small Cell Lung Cancer: An Effective Approach with Low Toxicity
ALEXANDROS ARDAVANIS, STELLA KOUMNA, IOANNIS FRAGOS, SAVVOULA MALLIOU, FLORA KYRIAKOU, IOANNIS MANTZARIS, ANDREAS SCORILAS, GERASSIMOS RIGATOS
Anticancer Research Jul 2008, 28 (4C) 2409-2415;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Erlotinib Monotherapy in Patients with Advanced Non-small Cell Lung Cancer: An Effective Approach with Low Toxicity
ALEXANDROS ARDAVANIS, STELLA KOUMNA, IOANNIS FRAGOS, SAVVOULA MALLIOU, FLORA KYRIAKOU, IOANNIS MANTZARIS, ANDREAS SCORILAS, GERASSIMOS RIGATOS
Anticancer Research Jul 2008, 28 (4C) 2409-2415;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • DYRK2 Expression May be a Predictive Marker for Chemotherapy in Non-small Cell Lung Cancer
  • Google Scholar

More in this TOC Section

  • Radiomics for Growth Prediction of Vestibular Schwannomas in Neurofibromatosis Type 2
  • Chemotherapy-induced Moderate to Severe Peripheral Neuropathy in Patients Receiving Adjuvant Radiotherapy for Breast Cancer
  • Efficacy and Prognostic Factors of Surgical Resection for Pulmonary Metastases From Ovarian Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire